The generic-patent medicine conflict flares up again in The Netherlands
Recently I reported in this journal1 how it became necessary for a judge to settle a dispute between the pharmaceutical industry and certain Dutch pharmacists. It considered the question of whether a pharmacist is permitted, without prior consultation, to give a patient a (cheaper) generic drug inst...
| Main Author: | |
|---|---|
| Format: | Electronic Article |
| Language: | English |
| Check availability: | HBZ Gateway |
| Journals Online & Print: | Drawer...
|
| Fernleihe: | Fernleihe für die Fachinformationsdienste |
| Published: |
BMJ Publ.
2006
|
| In: |
Journal of medical ethics
Year: 2006, Volume: 32, Issue: 9, Pages: 555 |
| Online Access: |
Volltext (JSTOR) Volltext (lizenzpflichtig) |
| Summary: | Recently I reported in this journal1 how it became necessary for a judge to settle a dispute between the pharmaceutical industry and certain Dutch pharmacists. It considered the question of whether a pharmacist is permitted, without prior consultation, to give a patient a (cheaper) generic drug instead of the patent drug mentioned on the prescription. Another dispute has now arisen after the pharmaceutical industry discovered that healthcare insurers were paying general practitioners (GPs) a bonus if they prescribed generic drugs, such as simvastatin (which reduces cholesterol content) or omeprazol (which reduces the … |
|---|---|
| ISSN: | 1473-4257 |
| Contains: | Enthalten in: Journal of medical ethics
|